Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2015 Jun 9;8(4):383–392. doi: 10.1161/CIRCOUTCOMES.114.000907

Figure 1. Distribution of CHADS2 and CHA2DS2-VASc Scores by Choice of Anticoagulation.

Figure 1

Figure 1

CHADS2 and CHA2DS2-VASc scores were lower among patients discharged on NOAC vs. warfarin therapy among AF patients hospitalized with ischemic stroke or TIA and discharged on either warfarin or NOAC (p<0.001 for difference in CHADS2 and CHA2DS2-VASc vs. warfarin).

AF indicates atrial fibrillation; NOAC, novel oral anticoagulant; CHADS2: C=congestive heart failure, H=hypertension, A=age ≥75, D=diabetes mellitus, S=prior stroke or TIA; CHA2DS2-VASc: CHADS2 plus V=vascular disease, A=age 65–74, S=female sex; TIA, transient ischemic attack